DEF 14A: Northwest Biotherapeutics Seeks Shareholder Approval for Capital Raise, Director Election

Northwest Biotherapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director election, auditor ratification, an increase in authorized common stock, and executive compensation.

Summary

• The Annual Meeting of Stockholders will be held on December 29, 2025, to vote on four key proposals.
• Proposals include the election of Mr. Pat Sarma as a Class II Director for a three-year term, ratification of Cherry Bekaert LLP as the independent registered public accounting firm for fiscal year 2025, and an advisory vote on 2024 executive compensation.
• A significant proposal is the approval of an amendment to the Certificate of Incorporation to increase authorized common stock from 1,700,000,000 to 2,600,000,000 shares.
• As of November 14, 2025, the company had 1,528,682,082 shares of common stock and 818,142 shares of preferred stock outstanding.
• The company acquired Advent BioServices, Ltd. on October 24, 2025, making it a wholly-owned subsidiary, after previously contracting with them for product development and manufacturing.
• Three milestones under Statement of Work #8 (SOW 8) for the DCVax-Direct program were completed as of December 31, 2024, related to basic technology transfer and process development.
• Executive compensation for 2024 includes approved but unpaid bonuses for the CEO ($300,000), former SVP & General Counsel ($250,000), and CTO ($180,000).
• The company reported a net loss of $(83,778) thousand in 2024, an increase from $(62,599) thousand in 2023.
• Total Shareholder Return (TSR) for a $100 investment (based on December 31, 2021) declined to $39 by the end of 2024, from $100 in 2023 and $111 in 2022.

Sentiment

Score: 3

Explanation: The significant decline in Total Shareholder Return and the increased net loss in 2024 indicate poor financial performance. The proposal to increase authorized shares by a large margin points to an ongoing need for capital, which will likely result in further shareholder dilution. While there are operational milestones achieved, the financial health and shareholder value trends are negative.

Positives

• Completion of three key milestones under SOW #8 for the DCVax-Direct program as of December 31, 2024, indicating progress in product development and manufacturing readiness.
• Acquisition of Advent BioServices, Ltd. on October 24, 2025, integrating a key development and manufacturing partner into a wholly-owned subsidiary, which could streamline operations and intellectual property control.
• The Board of Directors maintains a majority of independent members, and all key committees (Audit, Compensation, Conflicts, Nominations) are composed of independent directors, indicating adherence to corporate governance best practices.

Negatives

• Significant decline in Total Shareholder Return, with a $100 investment from December 31, 2021, decreasing to $39 by the end of 2024, indicating substantial value erosion for shareholders.
• Increased net loss in 2024 to $(83,778) thousand from $(62,599) thousand in 2023, signaling worsening financial performance.
• A substantial portion of executive bonuses for 2024 and 2023 remain unpaid, which could impact executive morale, retention, and suggests potential liquidity constraints.
• The need to increase authorized shares by 900,000,000 shares suggests ongoing and significant capital requirements, likely leading to further dilution for existing shareholders.
• The former Senior Vice President and General Counsel, Leslie Goldman, passed away on August 18, 2025, representing a loss of key management personnel.

Risks

• Dilution Risk: The proposed increase in authorized common stock from 1,700,000,000 to 2,600,000,000 shares is intended to raise additional capital, satisfy obligations for convertible securities, and provide equity incentives, which could lead to significant dilution for existing shareholders.
• Operational Funding Risk: The company explicitly states the need to raise capital for its operations, indicating potential ongoing funding challenges.
• Executive Retention Risk: Unpaid bonuses for executive officers for both 2024 and partially for 2023 could pose a risk to executive retention and motivation.
• Product Development Risk: The DCVax-Direct program involves pioneering and uncertainties, as highlighted by the previous contract with a different company that failed to produce products meeting specifications.
• Supply Chain Risk: A severe worldwide shortage of BCG, an essential reagent for DCVax-Direct, poses a risk to product manufacturing and requires the company to search for alternative agents.
• Anti-Takeover Effect: The increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have or be used for an anti-takeover effect, potentially entrenching current management.

Future Outlook

The company anticipates that if the increase in authorized common stock is approved, issuances may be made to raise additional capital, satisfy obligations for outstanding stock options, warrants, and convertible securities, and potentially provide equity incentives. The company's executive compensation program is designed to attract, retain, and incentivize executive officers to achieve progress in clinical programs and move towards eventual commercialization, while contending with ongoing challenges.

Management Comments

• Our success is highly dependent on our ability to attract, retain and incentivize executive officers who possess the skills, competencies and passion that are necessary to achieve progress in the Company’s clinical programs and progress toward eventual commercialization, as well as to contend with ongoing challenges to the Company’s progress.
• The pay of our Named Executive Officers should balance incentivizing performance, ensuring retention and building stockholder value and should be linked to the Named Executive Officers roles and contributions to the Company’s progress.
• The pay of our Named Executive Officers should retain and incentivize individual Named Executive Officers to perform multiple senior executive roles each, at least until such time as the Company’s progress and resources enable expansion of the management team.
• Our executive compensation program should enable us to recruit, develop, motivate and retain top talent. This is especially critical in a rapidly evolving field such as immuno-oncology, which requires highly specialized knowledge and experience and for which the talent pool is highly competitive.
• The Company greatly appreciates Mr. Goldman’s many years of intensive work on behalf of the Company, its stockholders and cancer patients.

Industry Context

The company operates in the highly competitive and rapidly evolving immuno-oncology field, which requires specialized knowledge and experience. The need to increase authorized shares for capital raising is common for biotechnology companies in clinical development, reflecting the significant funding requirements for R&D and potential commercialization. The worldwide shortage of BCG, a key reagent, highlights broader supply chain vulnerabilities in the biopharmaceutical industry.

Comparison to Industry Standards

• The company's significant net losses of $(83.8) million in 2024 and $(62.6) million in 2023 are typical for a biotechnology company in the clinical development stage, as substantial R&D and operational costs are incurred before product commercialization and revenue generation. For example, many early-stage biotech firms like Moderna (pre-COVID vaccine) or smaller oncology biotechs often report similar or larger losses during their development phases.
• The drastic decline in Total Shareholder Return (TSR) from $111 (2022) to $39 (2024) for a $100 investment starting December 31, 2021, is a concerning underperformance compared to broader market indices and many established or even successful clinical-stage biotech peers during the same period. For instance, the NASDAQ Biotechnology Index (NBI) might have shown volatility but a sustained decline of this magnitude over two years would be notable.
• The practice of approving but not fully paying executive bonuses, as seen with the CEO and former General Counsel for 2023 and 2024, is unusual and could signal liquidity constraints or performance-related issues, potentially deviating from standard executive compensation practices in the industry where bonuses are typically paid out upon approval.
• The acquisition of Advent BioServices, Ltd. to internalize manufacturing and development capabilities is a strategic move seen in the biotech industry to gain greater control over supply chains and intellectual property, similar to how companies like Gilead Sciences or Amgen have integrated key operational assets.

Management Changes

Corporate Governance

Related Party Transactions

• Acquisition of Advent BioServices, Ltd. on October 24, 2025, which was previously a related party providing contract services for product development, manufacturing, cryostorage, and distribution.
• Ongoing development and manufacturing programs with Advent BioServices, Ltd. under a Manufacturing Services Agreement (MSA) for the London facility (since May 14, 2018) and an Ancillary Services Agreement for the Sawston facility (since November 18, 2019, extended to July 2026).
• Statement of Work #8 (SOW 8) entered into on November 8, 2024, with Advent BioServices, Ltd. for the DCVax-Direct program in the U.K. and global manufacturing, with milestone payments upon successful completion. Milestones (a), (b), and (c) were completed as of December 31, 2024.
• Statement of Work #6 (SOW 6) involved baseline costs and one-time milestone incentives (cash and stock) for the Sawston facility, with $5.0 million cash and 4.5 million common shares (fair value $3.2 million) paid/issued in 2023.
• Linda F. Powers holds 56,992,773 warrants and 94,878,632 options, the majority of which were acquired from a third party or in connection with loans to the company, and are subject to a voluntary blocking agreement.
• Other named executive officers and directors hold an aggregate of 81,670,895 options and warrants subject to voluntary blocking agreements.

Stakeholder Impact

• Shareholders: Potential for significant dilution if the proposed increase in authorized common stock is approved and new shares are issued. Current shareholders have experienced substantial value erosion, as indicated by the Total Shareholder Return. The advisory vote on executive compensation allows shareholders to express their opinion on management's pay.
• Employees/Executives: Unpaid bonuses for executive officers could impact morale and retention. The passing of Leslie Goldman represents a loss of key personnel. The proposed increase in authorized shares could be used for equity incentives, potentially benefiting employees and directors.
• Customers/Patients: Progress in the DCVax-Direct program, including the completion of key milestones and the acquisition of Advent BioServices, could lead to advancements in product development and eventual commercialization, benefiting future patients.
• Creditors: The need to raise additional capital suggests ongoing financial requirements, which could be a factor for creditors.
• Suppliers: The acquisition of Advent BioServices, a key contract service provider, changes the relationship from a supplier to an internal operation. The worldwide shortage of BCG highlights potential supply chain challenges for other suppliers.

Next Steps

• Hold the Annual Meeting of Stockholders on December 29, 2025, to vote on the proposed matters.
• Issue a notice with information on how to access the audio-only connection for the Annual Meeting.
• File the Common Stock Increase Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware if approved by stockholders.
• Continue work on SOW #8 milestones (d) Technology Transfer: Clean Room Implementation and (e) New IMPD and New IND for the DCVax-Direct program.
• The company plans to enter into a new employment agreement with Ms. Powers.
• Stockholders can submit proposals for the next annual meeting by August 1, 2026, and advance notice for nominations/business between July 2, 2026, and August 1, 2026.
• Stockholders intending to solicit proxies for nominees must provide notice by October 30, 2026.

Key Dates

Recommendation

The company exhibits concerning financial trends, including a substantial increase in net loss in 2024 and a drastic decline in Total Shareholder Return over the past two years. The proposal to increase authorized common stock by over 50% explicitly for capital raising signals significant future dilution risk for existing shareholders. While operational progress is noted with the Advent acquisition and DCVax-Direct milestones, the underlying financial performance and the need for such a large capital raise suggest fundamental challenges that outweigh the positive developments. The unpaid executive bonuses further hint at potential liquidity issues. A seasoned investor would likely view these factors as strong indicators to sell or avoid the stock due to high risk and poor recent performance.

Keywords

Northwest Biotherapeutics, NWBO, Proxy Statement, Annual Meeting, Shareholder Vote, Authorized Shares, Common Stock Increase, Executive Compensation, Corporate Governance, Biotechnology, Immuno-oncology, DCVax-Direct, Capital Raise, Dilution, SEC Filing, Board of Directors, Audit Committee, Compensation Committee, Related Party Transaction, Advent BioServices, Financial Performance, Net Loss, Total Shareholder Return